The US FDA has approved the 40-ml dose of Multiple Sclerosis medication Copaxone from Israel’s Teva. The new higher dosage allows MS patients to reduce the number of injections from a daily frequency to just three times a week.
http://www.globes.co.il/en/article-fda-approves-tevas-longer-lasting-copaxone-1000912978